Catalent Announces New Organisation to Speed New Products to Market
![](/46/pdcnewsitem/03/42/80/zFwedt1GbiAR5br.png)
Catalent Pharma Solutions has announced that Sharon Johnson, Senior Vice President, Global Quality & Regulatory Affairs, is to head up Catalent’s newly formed Quality, Product Development & Regulatory Affairs organisation, established to further build upon Catalent’s leadership in new product development, regulatory excellence, reliable supply and quality.
One of the key functions of the new organisation will be to focus further on partnering with customers as part of Catalent’s New Product Introduction Excellence programme. An important factor in Catalent’s revenue and growth strategy, the programme has expanded at a rate of more than 70% over the past 3 years, from 59 new product launches globally in 2012, to 97 in 2013, and 175 in 2014.
“The overall goal of the Quality, Product Development & Regulatory Affairs organisation will be to drive excellence and reliability across all of the products that we make and deliver,” explained Johnson. “Our customer promise is not only to provide a reliable supply of their current, ongoing products, but to deliver new products with the same rigorous commitment to excellence. Bringing together these two functions into one team will tighten collaboration and the partnerships across the organisation which are needed to bring more new, innovative and life-saving products to market quicker.”
Ms Johnson will oversee a global function that includes more than 1500 scientists, quality professionals and regulatory affairs experts. Catalent’s 300 R&D scientists work across 20 global development teams to develop up to 500 new products at any one time. Catalent’s Quality and Regulatory Affairs teams have helped the company gain accreditation by over 30 global agencies, to supply more than 7000 products to in excess of 1000 customers. These products are delivered to over 80 countries, with Catalent maintaining a 100% success rate on new Pre-Approval Inspections (PAIs), and a regulatory inspections outcome rate that is two times better than the industry average.
Prior to assuming her new responsibilities, Ms Johnson had served as Catalent’s Senior Vice President, Global Quality & Regulatory Affairs since 2009, having overseen the roll-out of Catalent’s Global Quality Management system to over 20 global sites. Ms Johnson has more than 3 years of experience in the pharmaceutical industry, including API and multiple dosages forms, from discovery and launch of NCEs and life cycle management. Prior to joining Catalent, Ms Johnson served as Vice President of Quality for GE Healthcare’s Medical Diagnostic Division, having previously worked in roles of increasing responsibility for Baxter Healthcare and Sanofi Aventis.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance